Pharmaceutics
(Jun 2022)
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Camila Ordóñez-Reyes,
Juan Esteban Garcia-Robledo,
Diego F. Chamorro,
Andrés Mosquera,
Liliana Sussmann,
Alejandro Ruiz-Patiño,
Oscar Arrieta,
Lucia Zatarain-Barrón,
Leonardo Rojas,
Alessandro Russo,
Diego de Miguel-Perez,
Christian Rolfo,
Andrés F. Cardona
Affiliations
Camila Ordóñez-Reyes
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Juan Esteban Garcia-Robledo
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Diego F. Chamorro
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Andrés Mosquera
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Liliana Sussmann
Department of Neurology, Fundación Universitaria de Ciencias de la Salud, Bogotá 111221, Colombia
Alejandro Ruiz-Patiño
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Oscar Arrieta
Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), Mexico City 14080, Mexico
Lucia Zatarain-Barrón
Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), Mexico City 14080, Mexico
Leonardo Rojas
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
Alessandro Russo
Medical Oncology Unit, A.O. Papardo, 98158 Messina, Italy
Diego de Miguel-Perez
Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Christian Rolfo
Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Andrés F. Cardona
Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá 110111, Colombia
DOI
https://doi.org/10.3390/pharmaceutics14061243
Journal volume & issue
Vol. 14,
no. 6
p.
1243
Abstract
Read online
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strategy to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Here we discussed some basic aspects of the design and function of bsAbs, their main challenges and the state-of-the-art of these molecules in the treatment of hematological and solid malignancies and future perspectives.
Keywords
WeChat QR code
Close